-
11:04:19 AM

ANNX Stock News

05/24/23 4:01 PM
Nasdaq : ANNX
clinical trial
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
ARCHER data support ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection against vision loss in both foveal and non-foveal patients through 12 months Reduction in rate of geographic atrophy lesion growth did not reach statistical
RHEA-AI
neutral
01/08/23 9:00 AM
Nasdaq : ANNX
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with Operating Runway into 2025 Company to Present Pipeline Updates at 41 st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT
RHEA-AI
neutral